4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 2.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 440,665 shares of the company’s stock after purchasing an additional 9,982 shares during the quarter. Northern Trust Corp owned about 0.95% of 4D Molecular Therapeutics worth $2,455,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in FDMT. JPMorgan Chase & Co. grew its stake in shares of 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company’s stock worth $4,568,000 after purchasing an additional 504,086 shares during the period. Norges Bank acquired a new stake in 4D Molecular Therapeutics in the 4th quarter valued at about $2,790,000. Peapod Lane Capital LLC acquired a new stake in 4D Molecular Therapeutics in the 4th quarter valued at about $806,000. Raymond James Financial Inc. acquired a new stake in 4D Molecular Therapeutics in the 4th quarter valued at about $629,000. Finally, Vanguard Group Inc. grew its stake in 4D Molecular Therapeutics by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company’s stock valued at $15,933,000 after acquiring an additional 92,791 shares during the last quarter. 99.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Chardan Capital lowered their price objective on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Bank of America lowered their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Barclays lowered their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. Royal Bank of Canada lowered their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group lowered their price objective on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.56.

4D Molecular Therapeutics Trading Down 3.1%

NASDAQ:FDMT opened at $3.49 on Friday. The firm has a market cap of $161.67 million, a price-to-earnings ratio of -1.22 and a beta of 2.87. The company’s 50-day moving average is $3.25 and its two-hundred day moving average is $4.94. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.24 and a 12-month high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). On average, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.